Characterization of a Ruthenium(III)/NAMI‐A Adduct with Bovine Serum Albumin that Exhibits a High Anti‐Metastatic Activity

Abstract

An exchange for the better: X-ray absorption spectroscopic studies show that treatment of an RuIII drug, NAMI-A, with bovine serum albumin (BSA) results in complete replacement of the Cl− and S-donor ligands with N-donor and carboxylato residues of the protein (see scheme). The RuIII–BSA adduct is as active in enhancing the cell–substrate interactions as the original NAMI-A complex (which converts into RuIII–BSA within minutes in the cell-culture medium). Detailed facts of importance to specialist readers are published as ”Supporting Information”. Such documents are peer-reviewed, but not copy-edited or typeset. They are made available as submitted by the authors. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.